{
  "title": "Pharmacology of Antiplatelet, Hemostatic, Antimalarial, and Fibrinolytic Drugs",
  "module": "PHARM",
  "subject": "Pharmacology",
  "difficulty": "medium",
  "examTypes": ["USMLE", "PLAB"],
  "description": "Questions covering the mechanisms of action, side effects, antidotes, and indications of antiplatelet drugs, systemic hemostatics, antimalarial drugs, and fibrinolytic agents.",
  "questions": [
    {
      "id": "1",
      "type": "standard",
      "questionText": "What is the primary mechanism of action of aspirin as an antiplatelet agent?",
      "options": [
        "Inhibits ADP binding to platelet receptors",
        "Irreversibly acetylates cyclooxygenase (COX-1) in platelets",
        "Blocks GP IIb/IIIa receptors",
        "Increases intracellular cAMP levels"
      ],
      "correctAnswer": "Irreversibly acetylates cyclooxygenase (COX-1) in platelets",
      "explanation": "Aspirin inhibits platelet aggregation by irreversibly acetylating COX-1, preventing thromboxane A2 synthesis, which is essential for platelet aggregation.",
      "references": ["Document: pharma 2025.pdf, Page 1"],
      "difficulty": "medium"
    },
    {
      "id": "2",
      "type": "standard",
      "questionText": "How long does the suppression of platelet aggregation by aspirin last?",
      "options": [
        "1–2 days",
        "3–5 days",
        "7–10 days",
        "14–20 days"
      ],
      "correctAnswer": "7–10 days",
      "explanation": "Aspirin's suppression of platelet aggregation lasts for the lifespan of the platelet, approximately 7–10 days, as platelets are non-nucleated.",
      "references": ["Document: pharma 2025.pdf, Page 1"],
      "difficulty": "medium"
    },
    {
      "id": "3",
      "type": "standard",
      "questionText": "Which antiplatelet drug preferentially inhibits platelet COX-1 at low doses (<100 mg/day)?",
      "options": [
        "Clopidogrel",
        "Aspirin",
        "Ticlopidine",
        "Abciximab"
      ],
      "correctAnswer": "Aspirin",
      "explanation": "Low-dose aspirin (<100 mg/day) preferentially inhibits platelet COX-1, reducing thromboxane A2 synthesis while sparing systemic COX-2.",
      "references": ["Document: pharma 2025.pdf, Page 1"],
      "difficulty": "medium"
    },
    {
      "id": "4",
      "type": "standard",
      "questionText": "What is the mechanism of action of clopidogrel as an antiplatelet agent?",
      "options": [
        "Inhibits thromboxane A2 synthesis",
        "Blocks GP IIb/IIIa receptors",
        "Inhibits ADP binding to platelet receptors",
        "Increases cAMP by inhibiting phosphodiesterase"
      ],
      "correctAnswer": "Inhibits ADP binding to platelet receptors",
      "explanation": "Clopidogrel irreversibly inhibits ADP binding to its receptors on platelets, preventing activation of GP IIb/IIIa receptors required for platelet aggregation.",
      "references": ["Document: pharma 2025.pdf, Page 1"],
      "difficulty": "medium"
    },
    {
      "id": "5",
      "type": "standard",
      "questionText": "Which antiplatelet drug is associated with a risk of neutropenia?",
      "options": [
        "Clopidogrel",
        "Prasugrel",
        "Ticlopidine",
        "Eptifibatide"
      ],
      "correctAnswer": "Ticlopidine",
      "explanation": "Ticlopidine is associated with neutropenia as a side effect, which limits its clinical use compared to clopidogrel.",
      "references": ["Document: pharma 2025.pdf, Page 1"],
      "difficulty": "medium"
    },
    {
      "id": "6",
      "type": "standard",
      "questionText": "What is the mechanism of action of abciximab?",
      "options": [
        "Inhibits COX-1 enzyme",
        "Blocks GP IIb/IIIa receptors",
        "Inhibits ADP receptors",
        "Increases cAMP levels"
      ],
      "correctAnswer": "Blocks GP IIb/IIIa receptors",
      "explanation": "Abciximab is a monoclonal antibody that blocks platelet GP IIb/IIIa receptors, the final common pathway for platelet aggregation.",
      "references": ["Document: pharma 2025.pdf, Page 1"],
      "difficulty": "medium"
    },
    {
      "id": "7",
      "type": "standard",
      "questionText": "Which drug increases intracellular cAMP by inhibiting phosphodiesterase?",
      "options": [
        "Aspirin",
        "Clopidogrel",
        "Dipyridamole",
        "Abciximab"
      ],
      "correctAnswer": "Dipyridamole",
      "explanation": "Dipyridamole increases intracellular cAMP by inhibiting phosphodiesterase, reducing platelet aggregation, and is often used with aspirin.",
      "references": ["Document: pharma 2025.pdf, Page 2"],
      "difficulty": "medium"
    },
    {
      "id": "8",
      "type": "standard",
      "questionText": "What is the primary therapeutic use of dipyridamole?",
      "options": [
        "Monotherapy for myocardial infarction",
        "Combination with aspirin for cerebrovascular ischemia",
        "Treatment of pulmonary embolism",
        "Management of sickle cell anemia"
      ],
      "correctAnswer": "Combination with aspirin for cerebrovascular ischemia",
      "explanation": "Dipyridamole has little effect alone but provides additive benefits when combined with aspirin to prevent cerebrovascular ischemia.",
      "references": ["Document: pharma 2025.pdf, Page 6"],
      "difficulty": "medium"
    },
    {
      "id": "9",
      "type": "standard",
      "questionText": "What is the mechanism of action of desmopressin acetate as a systemic hemostatic?",
      "options": [
        "Induces inflammation in veins",
        "Releases factor VIII and von Willebrand factor",
        "Inhibits plasminogen activators",
        "Increases HBF formation"
      ],
      "correctAnswer": "Releases factor VIII and von Willebrand factor",
      "explanation": "Desmopressin acetate promotes hemostasis by releasing factor VIII and von Willebrand factor from vascular endothelium.",
      "references": ["Document: pharma 2025.pdf, Page 2"],
      "difficulty": "medium"
    },
    {
      "id": "10",
      "type": "standard",
      "questionText": "Which drug is used to treat sickle cell anemia by increasing HBF formation?",
      "options": [
        "Desmopressin",
        "Hydroxyurea",
        "Chloroquine",
        "Aminocaproic acid"
      ],
      "correctAnswer": "Hydroxyurea",
      "explanation": "Hydroxyurea is the first FDA-approved drug for sickle cell anemia, increasing fetal hemoglobin (HBF) formation.",
      "references": ["Document: pharma 2025.pdf, Page 2"],
      "difficulty": "medium"
    },
    {
      "id": "11",
      "type": "standard",
      "questionText": "How do chloroquine and hydroxychloroquine act as antimalarial drugs?",
      "options": [
        "Disrupt mitochondrial electron transport",
        "Prevent conversion of heme into hemozoin",
        "Inhibit dihydrofolate reductase",
        "Liberate free radicals"
      ],
      "correctAnswer": "Prevent conversion of heme into hemozoin",
      "explanation": "Chloroquine and hydroxychloroquine disrupt the erythrocytic stage of malaria by preventing the conversion of heme into hemozoin, increasing intracellular pH.",
      "references": ["Document: pharma 2025.pdf, Page 2"],
      "difficulty": "medium"
    },
    {
      "id": "12",
      "type": "standard",
      "questionText": "Which antimalarial drug is a hypnozoitocidal agent?",
      "options": [
        "Chloroquine",
        "Primaquine",
        "Mefloquine",
        "Doxycycline"
      ],
      "correctAnswer": "Primaquine",
      "explanation": "Primaquine acts as a hypnozoitocidal agent, targeting the dormant liver stage (hypnozoites) of Plasmodium as a protoplasmic toxin.",
      "references": ["Document: pharma 2025.pdf, Page 2"],
      "difficulty": "medium"
    },
    {
      "id": "13",
      "type": "standard",
      "questionText": "What is the mechanism of action of artemisinins in malaria treatment?",
      "options": [
        "Inhibit dihydrofolate reductase",
        "Disrupt mitochondrial electron transport",
        "Liberate free radicals",
        "Block protein synthesis"
      ],
      "correctAnswer": "Liberate free radicals",
      "explanation": "Artemisinins are active against all parasite lifecycle stages by liberating free radicals, causing oxidative damage to Plasmodium.",
      "references": ["Document: pharma 2025.pdf, Page 3"],
      "difficulty": "medium"
    },
    {
      "id": "14",
      "type": "standard",
      "questionText": "Which fibrinolytic drug causes a systemic fibrinolytic state?",
      "options": [
        "Alteplase",
        "Streptokinase",
        "Tenecteplase",
        "Tranexamic acid"
      ],
      "correctAnswer": "Streptokinase",
      "explanation": "Streptokinase converts plasminogen to active plasmin, causing a systemic fibrinolytic state and increasing bleeding risk.",
      "references": ["Document: pharma 2025.pdf, Page 3"],
      "difficulty": "medium"
    },
    {
      "id": "15",
      "type": "standard",
      "questionText": "Why are tissue plasminogen activators (t-PAs) preferred over streptokinase?",
      "options": [
        "Lower cost",
        "No risk of bleeding",
        "Lower risk of bleeding and no allergy",
        "Systemic fibrinolytic effect"
      ],
      "correctAnswer": "Lower risk of bleeding and no allergy",
      "explanation": "t-PAs (e.g., alteplase) selectively activate fibrin-bound plasminogen, reducing systemic bleeding and avoiding allergic reactions associated with streptokinase.",
      "references": ["Document: pharma 2025.pdf, Page 5"],
      "difficulty": "medium"
    },
    {
      "id": "16",
      "type": "standard",
      "questionText": "What is a side effect of prasugrel as an antiplatelet agent?",
      "options": [
        "Neutropenia",
        "Major and minor bleeding",
        "Dizziness",
        "Retinopathy"
      ],
      "correctAnswer": "Major and minor bleeding",
      "explanation": "Prasugrel is associated with an increased risk of major and minor bleeding, a significant side effect limiting its use.",
      "references": ["Document: pharma 2025.pdf, Page 3"],
      "difficulty": "medium"
    },
    {
      "id": "17",
      "type": "standard",
      "questionText": "Which antimalarial drug is associated with retinopathy as a side effect?",
      "options": [
        "Primaquine",
        "Chloroquine",
        "Doxycycline",
        "Pyrimethamine"
      ],
      "correctAnswer": "Chloroquine",
      "explanation": "Chloroquine is known to cause retinopathy, particularly with long-term use, as a significant adverse effect.",
      "references": ["Document: pharma 2025.pdf, Page 4"],
      "difficulty": "medium"
    },
    {
      "id": "18",
      "type": "standard",
      "questionText": "What is the antidote for heparin overdose?",
      "options": [
        "Vitamin K",
        "Protamine sulfate",
        "Idarucizumab",
        "Andexanet alpha"
      ],
      "correctAnswer": "Protamine sulfate",
      "explanation": "Protamine sulfate is the specific antidote for heparin, fully reversing unfractionated heparin (UFH) and partially reversing low-molecular-weight heparin (LMWH).",
      "references": ["Document: pharma 2025.pdf, Page 5"],
      "difficulty": "medium"
    },
    {
      "id": "19",
      "type": "standard",
      "questionText": "What is the antidote for dabigatran toxicity?",
      "options": [
        "Vitamin K",
        "Protamine sulfate",
        "Idarucizumab",
        "Deferoxamine"
      ],
      "correctAnswer": "Idarucizumab",
      "explanation": "Idarucizumab is a specific monoclonal antibody used to reverse the anticoagulant effects of dabigatran.",
      "references": ["Document: pharma 2025.pdf, Page 5"],
      "difficulty": "medium"
    },
    {
      "id": "20",
      "type": "standard",
      "questionText": "Which drug is used as an iron chelating agent for iron toxicity?",
      "options": [
        "Deferoxamine",
        "Idarucizumab",
        "Andexanet alpha",
        "Aminocaproic acid"
      ],
      "correctAnswer": "Deferoxamine",
      "explanation": "Deferoxamine is used as an iron chelating agent to treat iron toxicity by binding excess iron and promoting its excretion.",
      "references": ["Document: pharma 2025.pdf, Page 5"],
      "difficulty": "medium"
    },
    {
      "id": "21",
      "type": "standard",
      "questionText": "Which condition is an indication for fibrinolytic drugs?",
      "options": [
        "Chronic heart failure",
        "Acute myocardial infarction",
        "Hypertension",
        "Sickle cell anemia"
      ],
      "correctAnswer": "Acute myocardial infarction",
      "explanation": "Fibrinolytic drugs are indicated for acute myocardial infarction to dissolve thrombi and restore coronary blood flow.",
      "references": ["Document: pharma 2025.pdf, Page 6"],
      "difficulty": "medium"
    },
    {
      "id": "22",
      "type": "standard",
      "questionText": "Which antiplatelet drug is specifically indicated for stent insertion?",
      "options": [
        "Aspirin",
        "Clopidogrel",
        "Dipyridamole",
        "Abciximab"
      ],
      "correctAnswer": "Clopidogrel",
      "explanation": "Clopidogrel is commonly used in patients undergoing stent insertion to prevent stent thrombosis.",
      "references": ["Document: pharma 2025.pdf, Page 6"],
      "difficulty": "medium"
    },
    {
      "id": "23",
      "type": "standard",
      "questionText": "Which drug is commonly used for malarial chemoprophylaxis?",
      "options": [
        "Primaquine",
        "Atovaquone-Proguanil",
        "Hydroxyurea",
        "Tirofiban"
      ],
      "correctAnswer": "Atovaquone-Proguanil",
      "explanation": "Atovaquone-Proguanil is one of the most commonly prescribed medications for malarial chemoprophylaxis.",
      "references": ["Document: pharma 2025.pdf, Page 6"],
      "difficulty": "medium"
    },
    {
      "id": "24",
      "type": "standard",
      "questionText": "What is a side effect of mefloquine as an antimalarial drug?",
      "options": [
        "Retinopathy",
        "Seizure and psychosis",
        "Megaloblastic anemia",
        "Photosensitivity"
      ],
      "correctAnswer": "Seizure and psychosis",
      "explanation": "Mefloquine is associated with neurological side effects, including seizures and psychosis, particularly in susceptible individuals.",
      "references": ["Document: pharma 2025.pdf, Page 4"],
      "difficulty": "medium"
    },
    {
      "id": "25",
      "type": "standard",
      "questionText": "Why is clopidogrel preferred over prasugrel and ticlopidine?",
      "options": [
        "Lower cost",
        "Fewer side effects",
        "Faster onset of action",
        "No need for monitoring"
      ],
      "correctAnswer": "Fewer side effects",
      "explanation": "Clopidogrel is preferred due to fewer side effects compared to prasugrel (risk of bleeding) and ticlopidine (neutropenia).",
      "references": ["Document: pharma 2025.pdf, Page 5"],
      "difficulty": "medium"
    }
  ]
}